SCHEMBL7565906

SCHEMBL7565906

COc1ccc(CNC(=O)c2cc(C#N)ccc2NC2CCN(C=O)CC2)cc1OC

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.43
BACE1 P56817 1/20 0.43
ALDH1A1 P00352 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MMP2 P08253 1/20 0.42
MMP13 P45452 1/20 0.42
APEX1 P27695 1/20 0.41
PDE7A Q13946 1/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 2/20 0.41
MAPK1 P28482 1/20 0.41
TSHR P16473 1/20 0.40
MAPK10 P53779 1/20 0.40
PDE5A O76074 1/20 0.40
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7565006 0.95 PDE7A (0.44) ACHEBACE1ALDH1A1SMN1; SMN2MMP2
SCHEMBL7679020 0.95 PDE7A (0.44) ACHEBACE1ALDH1A1SMN1; SMN2MMP2
SCHEMBL7564997 0.95 PDE7A (0.44) ACHEBACE1ALDH1A1SMN1; SMN2MMP2
SCHEMBL7569009 0.91 ALDH1A1 (0.44) ACHEBACE1ALDH1A1SMN1; SMN2MMP2
SCHEMBL7564933 0.87 RAB9A (0.47) ACHEBACE1ALDH1A1MMP2MMP13
SCHEMBL7565400 0.86 ACHE (0.45) ACHEBACE1ALDH1A1SMN1; SMN2MMP2
SCHEMBL7598322 0.86 ACHE (0.45) ACHEBACE1ALDH1A1SMN1; SMN2MMP2
SCHEMBL7565390 0.86 ACHE (0.45) ACHEBACE1ALDH1A1SMN1; SMN2MMP2
Hydrochloric Acid SCHEMBL7389333 0.86 KDM4E (0.46) ALDH1A1SMN1; SMN2APEX1KDM4ELMNA
SCHEMBL7566674 0.86 ACHE (0.45) ACHEBACE1ALDH1A1SMN1; SMN2MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A ACHE 185/4885BACE1 2396/4885ALDH1A1 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.